VIDEX
LOE ApproachingNDAORALTABLET, CHEWABLEPriority Review
Approved
Oct 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIDEX is an oral small-molecule antiviral drug approved by Bristol Myers Squibb in 1991 for the treatment of HIV infection. The exact mechanism of action and pharmacologic class are not specified in available data, but it represents a foundational antiretroviral therapy from the early HIV treatment era. It is formulated as an oral tablet with chewable dosage options for patient convenience.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity and minimal current market activity; commercial team is likely small and focused on transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Comparing Side Effects of Two Forms of Videx in HIV-Infected Adults
200 enrolled
HIV Infections
A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)
HIV Infections
Career Relevance
VIDEX currently has zero linked job openings, reflecting its late-lifecycle stage and minimal commercial expansion. Career opportunities on this product are extremely limited, with any remaining roles focused on supply chain, compliance, and managed decline rather than brand building or market growth.
Worked on VIDEX at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.